• PRMT5, Splicing, and Glutamine Vulnerability in Neuroblastom

  2026-08-22

  The reference study shows that MYCN-amplified neuroblastoma is unusually dependent on PRMT5-controlled RNA splicing, epitranscriptomic regulation, and glutamine metabolism. Its integrated transcriptomic, isotope-tracing, genetic, and in vivo experiments connect spliceosomal disruption to reduced GLS protein and impaired glutamine utilization, providing a mechanistic framework for biomarker-guided metabolic studies.

• TRPV1 and TRPA1 Control of TSLP in Nasal Epithelium

  2026-08-22

  The reference study shows that TRPV1 and TRPA1 are expressed in nasal epithelial cells and can promote TSLP production through calcium influx and NFAT nuclear signaling. Its experimental design links epithelial ion-channel activation with inflammatory mediator release, while also distinguishing the stronger mechanistic evidence for TSLP from the more preliminary transcriptional and protein changes observed for IL-25 and IL-33.

• HotStart Universal 2X Green qPCR Master Mix Workflow

  2026-08-21

  Build a reproducible RT-qPCR workflow for studying TGF-β1–linked angiogenesis and osteo-immune coupling in diabetic foot ulcer models. This practical guide combines assay design, melt-curve verification, controls, and troubleshooting with the specificity advantages of a hot-start Taq polymerase.

• Oligomycin A and the Bioenergetics of Cell Fate

  2026-08-20

  Oligomycin A is more than a mitochondrial respiration inhibitor: it is a strategic probe for connecting ATP synthase function, ion homeostasis, reactive oxygen species, and cell fate. This article translates recent findings on sodium-driven mitochondrial energy failure into experimental guidance for cancer metabolism research, mitochondrial bioenergetics research, and apoptosis pathway study.

• TCAIM Control of OGDH and Mitochondrial Metabolism

  2026-08-20

  The 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. This mechanism links mitochondrial proteostasis to OGDH complex activity, carbohydrate catabolism, and broader metabolic regulation.

• Gepotidacin Mechanism at S. aureus Gyrase

  2026-08-19

  Gibson and colleagues combine biochemical assays with crystallography to show that gepotidacin inhibits Staphylococcus aureus gyrase through stable, predominantly single-stranded DNA cleavage complexes rather than the double-stranded breaks typically associated with fluoroquinolones. The work defines a distinct gyrase-binding mode and provides a mechanistic framework for studying antibacterial activity that may remain effective against some fluoroquinolone-resistant organisms.

• Measuring Drug Response Beyond In Vitro Viability

  2026-08-19

  Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a time-aware framework for separating proliferative arrest from cell killing, improving interpretation of in vitro pharmacology and experimental reproducibility.

• Equine Salmonella: TMP–Sulfonamide Synergy

  2026-08-18

  This study systematically measured the in vitro susceptibility of 62 equine Salmonella isolates to trimethoprim, nine sulfonamides, and their combinations across multiple concentration ratios. Its main contribution was showing that sulfachlorpyridazine, sulfadiazine, and sulfamethoxazole combined strong standalone activity with broad trimethoprim synergy, while resistance patterns limited the value of several other sulfonamides.

• HMGCS2, LysoPC, and Pulmonary Fibrosis

  2026-08-18

  Yang et al. identify injured type II alveolar epithelial cells as a major source of accumulated lysophosphatidylcholine in bleomycin-associated pulmonary fibrosis and show that LysoPC can activate lung fibroblasts. Their integrated lipidomic, transcriptomic, genetic, and AAV-based experiments connect epithelial HMGCS2 loss with impaired lipid degradation through a PPARα–CPT1A/CPT2 pathway, providing a mechanistic framework for epithelial–mesenchymal signaling in fibrosis.

• WIP1/PPM1D, p38 MAPK, and AKI Pyroptosis

  2026-08-17

  The reference study identifies WIP1/PPM1D as a negative regulator of p38 MAPK-dependent renal tubular pyroptosis in sepsis-associated acute kidney injury. By combining single-cell sequencing, patient and mouse tissue analyses, HK2-cell experiments, and pharmacological inhibition with CCT007093, it links PPM1D activity to inflammatory cell death and provides a framework for dissecting the PPM1D signaling pathway in kidney injury.

• PP2A, Autophagy, and C. albicans Biofilm Resistance

  2026-08-17

  The reference study identifies PP2A catalytic subunit PPH21 as a regulator of Candida albicans biofilm formation and antifungal resistance through ATG protein phosphorylation and autophagy. Its genetic, pharmacological, and mouse-model evidence connects PPH21–Atg13–Atg1 signaling with reduced treatment efficacy, while also defining important limits for translating the findings to other antifungal systems.

• Beyond Viability: Better In Vitro Drug Response Metrics

  2026-08-16

  Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. By separating growth inhibition from cell killing and considering their timing, the study offers a more precise framework for interpreting drug-response experiments and selecting appropriate follow-up assays.

• 3X (DYKDDDDK) Peptide: Workflows & Troubleshooting

  2026-08-15

  The 3X (DYKDDDDK) Peptide supports sensitive FLAG-based capture, competition, and assay validation without substantially increasing fusion-protein size. This guide connects practical purification and immunodetection workflows with structural studies of membrane enzymes, including PSS2 research and metal-sensitive assay design.

• Ganoderma Polysaccharide Boosts mRNA-LNP Efficacy

  2026-08-14

  A 2026 Pharmaceutics study identifies Ganoderma lucidum polysaccharide as an adjuvant that can improve mRNA-LNP protein expression while reducing carrier-associated oxidative stress. The work connects enhanced expression with glutathione and superoxide dismutase recovery, malondialdehyde reduction, and engagement of the Nrf2 pathway, offering a rationale for redox-aware delivery design.

• CCT007093: Practical PPM1D Assay Guidance

  2026-08-14

  Learn how CCT007093 (SKU B3274) can support mechanistic viability, proliferation, and cytotoxicity studies involving PPM1D and P38 MAPK signaling. This scenario-based guide covers assay design, solvent handling, pathway validation, interpretation, and practical product selection.

11511 records 1/768 page Next 12345 下5页 Last page